Podcasts about pcv13

In this episode, Lilian Abbo, MD, FIDSA; Julie Ann Justo, PharmD, MS; and David van Duin, MD, PhD, FIDSA, FAST, discuss key concepts about extraintestinal pathogenic Escherichia coli, including:Diverse strains and virulence factors associated with invasive diseaseAntimicrobial resistance profiles seen in clinical practiceVarious disease manifestationsPrevalence and burden of invasive infectionsPopulations at riskRisk factors for multidrug-resistant strainsEmerging vaccine technologiesActive clinical trials Benefits of vaccines and the challenges associated with developmentImportance of antimicrobial stewardship and potential role of vaccines to reduce antimicrobial resistanceProgram Director: Lilian Abbo, MD, FIDSAAssociate Chief Medical Officer in Infectious DiseasesJackson Health SystemProfessor of Infectious DiseasesDepartment of Medicine & Miami Transplant InstituteUniversity of Miami Miller School of MedicineMiami, FloridaFaculty:Julie Ann Justo, PharmD, MSClinical Associate ProfessorDepartment of Clinical Pharmacy and Outcomes SciencesUniversity of South Carolina College of PharmacyInfectious Diseases Clinical Pharmacy SpecialistDepartment of PharmacyPrisma Health Richland HospitalColumbia, South CarolinaDavid Van Duin, MD, PhD, FIDSA, FASTProfessor of Medicine Director, Immunocompromised Host Infectious Diseases ProgramDivision of Infectious DiseasesUniversity of North CarolinaChapel Hill, North CarolinaContent based on a CME program supported by an educational grant from Janssen Therapeutics.Follow along with a downloadable slideset at:https://bit.ly/3eG29BnLink to full program:https://bit.ly/3eFHfCl

In this episode, we will discuss the rationale behind the FDA approval of two new pneumococcal conjugate vaccines (PCV20 and PCV15), the characteristics of these vaccines, their place in therapy as recommended by the ACIP, and subsequent CDC immunization schedule changes. Key Concepts Pneumococcal disease is mainly caused by various serotypes of Streptococcus pneumoniae and presentation can vary from mild forms (sinusitis, otitis media) to more severe (pneumonia, bacteremia, or meningitis). Previously we used PCV13 and PPSV23 vaccines for adults ages 18 years and older for prevention of pneumococcal disease, but the recommendations were rather complicated based on age, underlying condition/immune status, and vaccination status.  Two new conjugate-type pneumococcal vaccines, PCV20 (Prevnar 20) and PCV15 (Vaxneuvance) are now approved by the FDA and were recently added to the CDC's adult immunization schedules. These updated recommendations are more simplified where adults with high-risk conditions and those ages 65 years and older should receive either 1 dose of PCV20 vaccine or 1 dose of PCV15 and then 1 dose of PPSV23 a year later to complete their pneumococcal vaccine series.   PCV15 is now FDA approved for children and updated recommendations for children have been voted upon by the Advisory Committee on Immunization Practices (ACIP) and will be final once it is made official policy by the CDC. References and Resources Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, et al. Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022. MMWR. 2022;71(4);109–117. https://www.cdc.gov/mmwr/volumes/71/wr/mm7104a1.htm?s_cid=mm7104a1_w Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. 14th ed. Hall E., Wodi A.P., Hamborsky J., et al., eds. Washington DC: Public Health Foundation; 2021. Goldblatt D, O'Brien KL. Pneumococcal Infections. In: Loscalzo J, Fauci A, Kasper D, Hauser S, Longo D, Jameson J. eds. Harrison's Principles of Internal Medicine 21e. McGraw Hill; 2022. Accessed August 04, 2022. Wagner AL, Boulton ML. Pneumococcal Infections. In: Boulton ML, Wallace RB. eds. Maxcy-Rosenau-Last Public Health & Preventive Medicine, 16e. McGraw Hill; 2022. Accessed August 04, 2022. CDC's PneumoRecs VaxAdvisor mobile app: https://www.cdc.gov/vaccines/vpd/pneumo/hcp/pneumoapp.html CDC's Pneumococcal vaccine timing for adults: https://www.cdc.gov/vaccines/vpd/pneumo/downloads/pneumo-vaccine-timing.pdf

Are your residents up-to-date with their pneumococcal vaccinations? Should they receive PCV13, PCV15, PCV20, or PPSV23 — and when? In today's episode, we break down the latest guidance from the Centers for Disease Control and Prevention (CDC) on pneumococcal conjugate vaccines (PCVs) and pneumococcal polysaccharide vaccines (PPSVs).We're joined by Debra Wright, Quality Improvement Specialist at Quality Insights. If you want to reach Debra directly, you can call her at 1-800-642-8686 ext 7636. You can also email her at dwright@qualityinsights.org.Related links in this episode: - Pneumococcal Vaccine Decision Tree by Quality Insights- CDC's Pneumococcal Vaccine Timing for AdultsCheck out our other interviews by visiting qualityinsights.org/qin/multimedia.  This material was prepared by Quality Insights, a Quality Innovation Network - Quality Improvement Organization under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication number 12SOW-QI-GEN-062322-CC-A.

In this first of two podcasts, Tracey M. Piparo, PA-C and Martin C. Mahoney, MD, PhD discuss the benefits of pneumococcal vaccination, review the types of pneumococcal vaccines currently available, and provide ACIP's recently updated age-based and risk-based recommendations on when to use the new conjugated pneumococcal vaccines.  This activity is available for CE/CME credit. Claim your credit at pce.is/pneu.Contributors:Martin C. Mahoney, MD, PhDProfessorDepartment of Epidemiology and Environmental HealthUniversity of BuffaloProfessor of OncologyRoswell Park Comprehensive Cancer CenterBuffalo, New YorkDr Mahoney: consulting fees: Pfizer; consulting fees/fees for non-CME/CE services: Merck; fees for non-CME/CE services: GlaxoSmithKline, Sanofi.Tracey M. Piparo, PA-CPalliative MedicineRWJ Barnabas HealthNew Brunswick, New JerseyImmediate Past PresidentNew Jersey State Society of Physician AssistantsMs. Piparo has no relevant financial relationships to disclose.

In this episode, Martin C. Mahoney, MD, PhD, discusses new data on vaccine-preventable diseases from IDWeek 2021, including:Pneumococcal diseaseRespiratory syncytial virus (RSV)Herpes zosterInfluenzaPresenter:Martin C. Mahoney, MD, PhD  Professor of OncologyDepartment of Internal MedicineRoswell Park Comprehensive    Cancer InstituteBuffalo, New York  Follow along with an expanded slideset at:https://bit.ly/3Ev8ozrLink to full program:https://bit.ly/3BCHF2E

肺炎鏈球菌疫苗最近被打爆了。這篇帶大家來看看目前的一些證據。 等不到新冠疫苗先打肺炎鏈球菌疫苗？教授駁斥：完全無此建議 https://health.udn.com/health/story/120951/5529292 林慶順教授表示： 一篇2021-3-9發表的論文，標題是Prevention of COVID-19 among older adults receiving pneumococcal conjugate vaccine suggests interactions between Streptococcus pneumoniae and SARS-CoV-2 in the respiratory tract（接種肺炎球菌結合疫苗的老年人預防新冠肺炎表明肺炎鏈球菌和新冠病毒在呼吸道中存在相互作用）。 這項研究檢查了 2020 年 3 月 1 日至 7 月 22 日期間南加州 Kaiser Permanente 醫院的531,033 名 65 歲及以上病患的電子健康記錄，發現有接種過 PCV13 肺炎鏈球菌疫苗的人比沒有接種過PCV13 肺炎鏈球菌疫苗的人，不論是新冠肺炎的確診、住院，還是死亡，都降低三成多。 從這篇文章的標題以及討論就可以看出，它所要傳達的訊息是「肺炎鏈球菌與新冠病毒在呼吸道中似乎有相互作用」。但是，從頭到尾，它完全沒有提出建議，說民眾需要接種肺炎鏈球菌疫苗來預防新冠肺炎。 施打肺炎球菌疫苗來預防新冠肺炎並沒有得到醫學界的認可。縱然是那項加州大學的研究，也完全沒有提出「施打肺炎球菌疫苗來預防新冠肺炎」的建議。而且，請注意，那項加州大學的研究只是看「有沒有打過肺炎球菌疫苗」，但卻沒有看「疫苗施打的時間點」。所以，「臨時抱佛腳的施打肺炎球菌疫苗」是否能預防新冠肺炎，更是未知數中的未知數。 04b解讀：有些證據顯示打過13價肺炎鏈球菌疫苗，新冠肺炎的確診、住院，還是死亡都有降低。但也有其他研究無法複製這發現。我個人會建議如果近期有需要去醫院就診，順便施打的話可以考慮。但不要在這種時候專程到醫院只為施打這個13價肺炎鏈球菌疫苗，特別是在雙北，此時去醫院是很容易遇到新冠病毒的。 高端 聯亞 國產疫苗懶人包 第二期結束就緊急授權可行嗎？ https://linshibi.com/?p=39547 新冠快篩懶人包 普篩 抗體快篩 抗原快篩 https://linshibi.com/?p=36564 新冠肺炎疫情下的防疫須知 常見問題解答FAQ https://linshibi.com/?p=35408 新冠疫苗常見問題懶人包 https://linshibi.com/?p=38945 林氏璧醫師的電子名片 https://lit.link/linshibi 歡迎贊助我喝咖啡 https://pay.firstory.me/user/linshibi Powered by Firstory Hosting

Episode 20: Baby BluesThe sun rises over the San Joaquin Valley, California, today is Jul 17, 2020.It feels good to talk about prevention when an effective and safe vaccine is actually available! This is the case for the Pneumococcal Conjugate Vaccine 13 (PCV13 or Prevnar 13®).  In November 2019, the CDC issued an update on PCV13 vaccination. PCV13 vaccination for ALL immunocompetent adults 65 years and older is NOT recommended. Instead, it is recommended to make a shared decision when these patients do NOT have an immunocompromising condition, CSF leak, or cochlear implant, and have not previously received PCV13. Some candidates for PCV13 include patients residing in areas with low pediatric PCV13 uptake; those traveling to settings with no pediatric PCV13 program; those with chronic heart, lung, and/or liver disease, diabetes, or alcoholism; and those who smoke. PCV13 is still recommended in a series with Pneumovax® (PPSV23) for all adults 19 years and older (including those 65 years and older) with immunocompromising conditions, CSF leaks, or cochlear implants. A single dose of Pneumovax® for ALL adults 65 years and older is still recommended (1,2).____________________________“Perfection is not attainable, but if we chase perfection we can catch excellence.” –Vince LombardiPerfection is a very complex concept. Have you seen a surgery that was performed perfectly? I have. Believe it or not, there are perfect surgeries. Some musicians can play a song perfectly. I think perfection in some areas may be attainable. Another example, I think a person can be perfectly punctual for a time. That’s perfection. However, in most cases, perfection may not be attainable, but we should at least aim for excellence. And today, we have a resident who is in her pursuit of excellence, she is doing very good in her residency. Her voice may be familiar to you because she has recorded many of our introductions, and people have loved her voice. Welcome Dr Der Mugrdechian. Question Number 1: Who are you?  My name is Alyssa Der Mugrdechian, I am a 2nd-year resident in the Rio Bravo Family Medicine Program here in Bakersfield. I am a native to the Central Valley having grown up in Fresno, California. I am of Armenian descent and my family settled in California after surviving the Armenian Genocide in 1915. Coming from a family of mostly educators, I am the first to pursue Medicine.  I went to UC Irvine for undergrad and majored in Biological Sciences, and my journey to becoming an MD took me to Ross University on the beautiful island of Dominica.  Though I have traveled a lot during my schooling, I am happy to have the opportunity to have returned to the Central Valley to complete my residency training in an underserved community close to my family and friends.  For fun, I like to draw/paint, I also enjoy cooking, traveling, going to the beach and going to any Disney park as often as possible. Question number 2: What did you learn this week? This month my rotation is Gynecology. I am generally seeing patients for gynecologic issues, OB follow ups and routine post-partum visits. During these appointments, a very important question that can often be overlooked is whether the patient is coping with post-partum depression. Furthermore, another important distinction to make is if it is in fact major depression vs. baby blues. Post-partum Depression (PPD) The post-partum period can encompass the first 12 months after giving birth, however there’s no set length that’s been agreed upon.  Major depression is not confined to the post-partum stage, it can also arise during pregnancy. Factors that increase risk of developing Post-Partum Depression (PPD):Antenatal depressive symptomsHistory of Major Depressive DisorderPrevious Post-Partum Depression Other factors to take into consideration are home life, socioeconomic factors, previous or current abusive relationships/situations.  Edinburgh Postnatal Depression scale The EPDS is a screening tool for postpartum depression. It consists of 10 questions. The test can usually be completed in less than 5 minutes. Responses are scored 0, 1, 2, or 3 according to increased severity of the symptom. Some items are reverse scored (i.e., 3, 2, 1, and 0). You add scores of each question to get a total score. Cut-off scores range from 9 to 13 points. It requires clinical judgment to determine the right timing for referral. For example, if a woman scores 9 or indicating any suicidal ideation, she most likely would benefit from immediate referral. “In women without a history of postpartum major depression, a score above 12 has a sensitivity of 86 percent and specificity of 78 percent for postpartum major depression. You can find the hand out at the end of this document.Other screening methods include PHQ-9, and diagnosis is based on DSM-5.      Distinguishing Between “Baby Blues” and Postpartum Major DepressionCHARACTERISTICBABY BLUESPOSTPARTUM MAJOR DEPRESSIONDurationLess than 10 daysMore than two weeksOnsetWithin two to three days postpartumOften within first month; may be up to one yearPrevalence80 percent5 to 7 percentSeverityMild dysfunctionModerate to severe dysfunctionSuicidal ideationNot presentMay be present Diagnosis and Treatment Labs can also be considered, including TSH to rule out other causes of depressive symptoms Treatment can include both pharmacologic and non-pharmacologic methods such as psychotherapy (interpersonal, cognitive behavioral therapy) Selective serotonin reuptake inhibitors — SSRIs are widely prescribed in lactating women. Breastfeeding should not be discouraged during treatment with SSRIs.DRUGSTARTING DOSAGEUSUAL TREATMENT DOSAGEMAXIMAL DOSAGEADVERSE EFFECTSSelective serotonin reuptake inhibitorsCitalopram (Celexa)10 mg20 to 40 mg60 mgHeadache, nausea, diarrhea, sedation, insomnia, tremor, nervousness, loss of libido, delayed orgasmEscitalopram (Lexapro)5 mg10 to 20 mg20 mgFluoxetine (Prozac)10 mg20 to 40 mg80 mgParoxetine (Paxil)10 mg20 to 40 mg50 mgSertraline (Zoloft)25 mg50 to 100 mg200 mgSerotonin-norepinephrine reuptake inhibitorsDesvenlafaxine, extended release (Pristiq)50 mg50 mg100 mgHeadache, nausea, diarrhea, sedation, insomnia, tremor, nervousness, loss of libido, delayed orgasm, sustained hypertensionDuloxetine (Cymbalta)20 mg30 to 60 mg60 mgSame as selective serotonin reuptake inhibitorsVenlafaxine, extended release (Effexor XR)37.5 mg75 to 300 mg300 mgSame as desvenlafaxine  Question number 3: Why is this knowledge important for you and your patients? Sometimes patients aren’t willing or open to discussing this topic. In other cases, it may not even be touched upon by providers following up with the patients. But especially with everything going on this year with the pandemic, mental health is vital to a patient’s overall well-being. It also affects maternal functioning, and ultimately the well-being of the child It can lead to lack of breastfeeding, lack of maternal-infant bonding, problems with abnormal child development, problems with infants sleeping properly and also receiving the proper vaccinations. Suicide can also occur, however this rate is very low in the post-partum period  Question number 4: How did you get that knowledge?I got interested in the topic because of the patients I have seen in clinic. I consulted reliable sources such as UpToDate, our day-to-day companion in clinic; American Academy of Family Physician; and the United States Preventive Services Task Force, which is our main source of preventive services offered in Family Medicine. Question number 5: Where did you get the information from?An article by Dr Viguera about Postpartum depression in UpToDate, updated on 11/20/2018. I also consulted an article about safe infant exposure to antidepressants in UpToDate. AAFP has a very good source of information about Postpartum depression. See details below. Edinburgh Postnatal Depression ScaleEdinburgh Postnatal Depression Scale. © 1987 The Royal College of Psychiatrists. The Edinbugh Postnatal Depression Scale may be photocopied by individual researchers or clinicians for their own use without seeking permission from the publishers. The scale must be copied in full and all copies must acknowledge the following source: Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987;150:782–786. Written permission must be obtained from the Royal College of Psychiatrists for copying and distribution to others or for republication (in print, online or by any other medium). Translations of the scale, and guidance as to its use, may be found in Cox JL, Holden J. Perinatal Mental Health: A Guide to the Edinburgh Postnatal Depression Scale. London: Gaskell; 2003.  Speaking Medical: Borborygmusby Max Uschuk, MS4 We all have been in a silent exam and your stomach decides to demonstrate the sound of a humpback whale mating call. That’s borborygmus. What is borborygmus besides an interesting word to say? Technically speaking it is peristaltic movement of gas and fluid through the intestines causing an audible sound that is loud enough to be heard by the naked ear. When someone says their stomach is growling or rumbling, that is borborygmus or borborygmi (plural), not to be confused with bowel sound or peristaltic sounds which require a stethoscope to be heard. Is it medically pertinent? Many things can cause borborygmus. An empty stomach around 2 hours post prandial starts to signal the brain that it is fasting, it triggers peristaltic waves every 90-230 min, and contents are moved through the intestines and function to inhibit migration of bacteria from the large intestine to the small intestine. This movement can cause borborygmus. When someone swallows air while talking, eating or drinking it can increase borborygmus. Incomplete digestion of foods such as milk, gluten, fruits and vegetables, bean, legumes, and high fiber foods can increase borborygmus. Now, this can be normal but when paired with bloating, pain, diarrhea or constipation it can be indicative of a pathological process. Some pathologies such as celiac disease, colitis due to infection or necrotizing colitis, diverticulitis, irritable bowel syndrome, carcinoid syndrome or basically anything that really irritates the intestines can cause borborygmus. From the Practical Medicine Series; General Surgery, “the presence of stormy peristalsis or borborygmus in the absence of fever may be considered pathognomonic to intestinal obstruction as it never occurs in adynamic ileus” Thank you for listening and I hope you get to use the word borborygmus sometime soon. ____________________________Espanish Por Favor: Spanish Last Namesby Dr Claudia Carranza“Hola, me llamo Fernando Hernandez Guerrero Fernandez Guerrero.”That’s a fictional name from Fuller House, but sometimes that’s how Hispanic names sound like to English speakers. Hi, this is Dr Carranza in our section Espanish por favor, today instead of bringing you a word of the week I wanted to discuss a topic with everyone. It’s the topic of last names! In the States, people usually have one last name, unless once married they chose to hyphenate their last name. Well, in the Hispanic culture we usually have 2 last names. The last names we have are first, our father’s last name, and our second, our mother’s last name.  So, for example, my name is Claudia Carranza, but the name given to me at birth was: Claudia Roxana Carranza Guzman. I don’t think I have ever met anyone in Peru (where I’m from) that only had one last name. Dr Arreaza brought up an interesting point, which is what if people in Latin American cultures have one last name? I’ll let him expand on this topic. Dr Arreaza: Having only one last name may have a negative social connotation. When someone has one last name in Venezuela it usually means that you are a “natural son”, or illegitimate, or born from a single mother. Dr Carranza: In Peru, at least what I saw growing up, if a child only had one parent then they took the full first and second last name of that parent. So, guys when you meet a Hispanic patient with two last names, remember that their 1st last name is the one they will usually go by, not the second. So, for my name Claudia Roxana Carranza Guzman, you would call me: Claudia Carranza, not Claudia Guzman. Hope this helps when you are trying to figure out what last name to use when you see a patient or have a coworker with 2 last names!____________________________For your Sanity: by Steven Saito and Tana ParkerDoctor: I have bad news, and very bad news.Patient: What's the bad news?Doctor: You only have 24-hours to livePatient: And the really bad news?Doctor: I’ve been trying to contact you since yesterday._______________________________Now we conclude our episode number 20 “Baby Blues”. Dr Der Mugrdechian reminded us to screen for post-partum depression using the Edinburg Postnatal Depression Scale and make sure it is not “baby blues.” Max taught us the word borborygmus, just a fancy way to say “very loud stomach growling,” and Dr Carranza explained that the name you see at the end of a looooong Spanish name may not be the actual last name. The actual last name is the name before the last, I know it may be confusing, but it’s OK to ask your patients their preferred last name.     This is the end of Rio Bravo qWeek. We say good bye from Bakersfield, a special place in the beautiful Central Valley of California, United States, a land where growing is happening everywhere.If you have any feedback about this podcast, contact us by email RBresidency@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. This podcast was created with educational purposes only. Visit your primary care physician for additional medical advice. Our podcast team for this episode is Hector Arreaza, Alyssa Der Mugrdechian, Claudia Carranza, Lisa Manzanares, and Max Uschuk (pronounced Use-Chuck). Audio edition: Suraj Amrutia. See you soon! _____________________References:Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Updated Recommendations of the Advisory Committee on Immunization Practices, Weekly, November 22, 2019 / 68(46);1069–1075, https://www.cdc.gov/mmwr/volumes/68/wr/mm6846a5.htm#T1_downShared Decision-Making for Administering PCV13 in Older Adults, AMIT A. SHAH, MD; MARK R. WALLACE, MD; and HEATHER FIELDS, MD, Mayo Clinic, Scottsdale, Arizona, Am Fam Physician. 2020 Feb 1;101(3):134-135. https://www.aafp.org/afp/2020/0201/p134.html Viguera, Adele MD. “Postpartum unipolar major depression: Epidemiology, clinical features, assessment, and diagnosis” UptoDate. Last updated 11/20/2018. Mary C Kimmel, MD, Samantha Meltzer-Brody, MD, MPH, “Safety of infant exposure to antidepressants and benzodiazepines through breastfeeding” UptoDate. Last updated 11/10/2019. KATHRYN P. HIRST, MD, and CHRISTINE Y. MOUTIER, MD, University of California, San Diego, School of Medicine, La Jolla, California. “Postpartum Major Depression”, Am Fam Physician. 2010 Oct 15;82(8):926-933. https://www.aafp.org/afp/2010/1015/p926.html      

Credits: 0.25 AMA PRA Category 1 Credit™ Claim CME/CE credit: https://www.pri-med.com/online-education/podcast/seize-the-day-pt-2 Overview: Adults between the ages of 18 through 64 with immunocompromising conditions due to either anatomic defects or impaired immune response are at the highest risk for invasive pneumococcal disease. They need two different pneumococcal vaccines: pneumococcal conjugate vaccine (PCV13) at the time the risk factor is recognized and pneumococcal polysaccharide vaccine (PPSV23) at least 8 weeks later. This podcast will discuss how to identify these patients at high risk for pneumococcal disease and implement guidelines for administration of pneumococcal vaccination in this population. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/18/2020 and they are subject to change as new information is published. Guest: Robert H. Hopkins Jr, MD, MACP, FAAP

Credits: 0.25 AMA PRA Category 1 Credit™ Claim CME/CE credit: https://www.pri-med.com/online-education/podcast/seize-the-day-pt-1 Overview: The Advisory Committee on Immunization Practices (ACIP) makes shared clinical decision-making recommendations when individuals may benefit from vaccination, but broad vaccination of all people in that group is unlikely to have population-level impact. Such a recommendation is applicable to pneumococcal vaccines whereby pneumococcal conjugate vaccine (PCV13) is recommended for all adults 65 and older, while the administration of pneumococcal conjugate vaccine (PCV13) is based on shared decision-making. In this podcast, we will discuss the ACIP recommendations and the use of shared decision-making as it applies to pneumococcal vaccines. Please note that any data, indications, and guidelines presented in this activity are current as of the recording on 6/18/2020 and they are subject to change as new information is published. Guest: Robert H. Hopkins Jr, MD, MACP, FAAP

Here are the links for everything discussed in Episode 12. Approval of Givlaari for AHP Approval of Calquence for CLL & SLL The 5th biosimlar approved for Humira - Abrilada Approval of Exservan for ALS New treatment for Sickle Cell Disease - Oxbryta Updated CDC guidelines for PCV13 Connect with The Rx Daily Dose:Twitter      Instagram      YouTube      Linkedin       WebsiteEmail: therxdailydose@gmail.comConnect with Ian Parnigoni PharmD. on social media:Twitter       Instagram       Linkedin  ★ Support this podcast on Patreon ★

Dr Kimberly Manning joins to discuss imposter syndrome, how vacations affect health, and an update on the pneumonia vaccine, PCV13. Plus, hot takes on the dangers of vaping, and using procalcitonin and CRP to determine need for antibiotics.  Howdy, gentle listeners! It’s that special time of year when the school doors reopen, classrooms are awash in ‘new pencil’ smell, and FOAMed fans grab their trays and head to the cafeteria for some tasty knowledge food. Rest assured your Curbsiders friends have saved you a seat at the lunch table for this very special September 2019 episode!  Today we are joined by Dr. Kimberly Manning MD, FACP, FAAP, who is an Associate Professor of Medicine at Emory University School of Medicine. Dr. Manning authors a blog (“Reflections of a Grady Doctor”) that was named in 2010 by ‘O’ The Oprah Magazine as one of “four top medical blogs you should read.” She can also be found on Twitter, @gradydoctor. Thanks for listening! Full show notes at https://thecurbsiders.com/episode-list. Rate us on iTunes, recommend a guest or topic and give feedback at thecurbsiders@gmail.com. Credits  Written and Produced by: Sarah Phoebe Roberts MPH, Christopher Chiu MD, FACP, FAAP Hosts: Matthew Watto MD, FACP; Sarah Phoebe Roberts MPH, Paul Williams MD, FACP; and Christopher Chiu MD, FACP, FAAP Editor: Christopher Chiu MD, FACP, FAAP; Emi Okamoto MD Cover-Art: Christopher Chiu MD, FACP, FAAP Guest: Kimberly Manning MD, FACP, FAAP Time stamps 00:00 Introduction/Disclaimer 03:15 Guest bio 05:00 Getting to know Dr. Manning 11:05 Picks of the week*: Reflections of a Grady Doctor, Dr. Kimberly Manning’s Blog; To Kill a Mockingbird by Harper Lee, audiobook narrated by Sissy Spacek; LeVar Burton Reads, a podcast; Aziz Ansari Right Now (comedy special) and Master of None (TV show); Garfield Minus Garfield, an existential take on a classic comic; Clue, the 1985 movie 17:15 Paul’s vaping update (CDC media statement) 20:10 Procalcitonin, CRP and antibiotic prescription for COPD exacerbation 24:30 Pneumococcal conjugate vaccine 30:00 Imposter syndrome 49:00 Vacation time and metabolic syndrome 57:00 Wrap-up and outro *The Curbsiders participates in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising commissions by linking to Amazon. Simply put, if you click on my Amazon.com links and buy something we earn a (very) small commission, yet you don’t pay any extra.

PCV13 shows moderate overall effectiveness for preventing invasive pneumococcal disease caused by PCV13 vaccine serotypes in adults 65 years and older (http://bit.ly/2QtUXGW). Also today, ED visits that are related to psychiatric complaints are up 20 among elderly (http://bit.ly/2xVmmus), nonobstructive angina should trigger functional testing (http://bit.ly/2Nk6TJk), and antibiotics trigger proteolytic activity that leads to chronic colitis (http://bit.ly/2zP0n9P).

This episode features Dr. Sheldon Kaplan discussing the use of a third dose of the MMR vaccine for the prevention of mumps in an outbreak setting. Dr. Jennifer Mitty hosts. Dr. Kaplan is Professor of Pediatrics and head of the Pediatric Infectious Disease section at Baylor College of Medicine, and he is Chief of the Infectious Disease service and head of the Department of Pediatric Medicine at Texas Children's Hospital in Houston. References: Marin M, Marlow M, Moore KL, et al. Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak. MMWR Morb Mortal Wkly Rep 2018; 67:33. Cardemil CV, Dahl RM, James L, et al. Effectiveness of a Third Dose of MMR Vaccine for Mumps Outbreak Control. N Engl J Med 2017; 377:947. Contributor Disclosure: Grant/Research/Clinical Trial Support: Pfizer [Streptococcus pneumonia (PCV13, linezolid)]; Merck [Staphylococcus aureus (Tedizolid)]; Allergen [Osteomyelitis (Ceftaroline)]. Consultant/Advisory Boards: Pfizer [Staphylococcus aureus (vaccine development); linezolid]. Other Financial Interest: Pfizer [Speaker on PCV13, linezolid]; Medscapre [Video discussion on bacterial meningitis]; Elsevier [Co-editor (Feigin and Cherry Textbook of Pediatric Infectious Diseases)].

This episode features Dr. David Nathan, discussing the diabetes drug, empagliflozin, and its impact on diabetes and cardiovascular outcomes (01:07); Dr. John Bartlett, discussing revisions to US recommendations for pneumococcal vaccination in older adults (09:30); and Dr. Mason Freeman, discussing use of the newly approved PCSK9 antibodies in the treatment of hyperlipidemia (17:53). Dr. Nancy Sokol hosts. Podcast References 1. Segment on empagliflozin (Dr. Nathan): Zinman, B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373:2117. 2. Segment on pneumococcal vaccination (Dr. Bartlett): Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015; 64:944. 3. Segment on PCSK9 antibodies (Dr. Freeman): Robinson JG, Farnier M, Krempf M et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1488. Sabatine MS, Giugliano RP, Wiviott SD et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372:1500.